AbbVie Issues Optimistic 2013 View on Strong Humira Sales
01/30/2013| 08:36am US/Eastern
By Melodie Warner
AbbVie Inc. (>> AbbVie Inc) issued an optimistic 2013 forecast as it expects strong sales of the rheumatoid arthritis drug Humira to continue.
AbbVie is the research-based pharmaceutical business spun off from Abbott Laboratories (>> Abbott Laboratories) last month.
The company estimated 2013 adjusted earnings at $3.03 to $3.13 a share, while analysts polled by Thomson Reuters expect $3.08 a share.
Abbott had previously said fourth-quarter sales of Humira jumped 23% to $2.68 billion.
AbbVie said it expects the drug's sales to increase by a low double-digit percentage in 2013.
The company also said it plans to initiate several Phase III programs this year, including atrasentan for diabetic kidney disease and ABT-199 in chronic lymphocytic leukemia.
Shares closed Tuesday at $37.31 and were inactive premarket. The stock has climbed 9.2% so far this year.
Write to Melodie Warner at email@example.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires